Personalis (NASDAQ:PSNL) Coverage Initiated by Analysts at Guggenheim

Research analysts at Guggenheim began coverage on shares of Personalis (NASDAQ:PSNL) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $6.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 21.21% from the company’s previous close.

A number of other research firms also recently weighed in on PSNL. HC Wainwright increased their target price on Personalis from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, May 7th. Craig Hallum began coverage on Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $7.67.

Personalis Price Performance

PSNL stock opened at $4.95 on Thursday. Personalis has a 1-year low of $1.14 and a 1-year high of $7.20. The business has a fifty day moving average price of $3.76 and a 200-day moving average price of $4.46. The stock has a market capitalization of $437.21 million, a P/E ratio of -2.95 and a beta of 1.83.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The company had revenue of $20.61 million for the quarter, compared to the consensus estimate of $17.41 million. As a group, analysts anticipate that Personalis will post -1.4 earnings per share for the current year.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Personalis during the 4th quarter valued at approximately $28,000. JPMorgan Chase & Co. increased its stake in Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after acquiring an additional 5,654 shares during the last quarter. Olympiad Research LP bought a new stake in Personalis in the 4th quarter worth approximately $59,000. Alpine Global Management LLC bought a new stake in Personalis in the 4th quarter worth approximately $60,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Personalis by 18.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company’s stock worth $62,000 after acquiring an additional 2,724 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.